Skip to content
Screener

AnaptysBio, Inc. ANAB Q4 2024 Annual earnings

Reported February 27, 2025 · After market close

Revenue$43.1MBeat by $35.3M
EPS-$0.72Beat by $0.83
Revenue estimate$7.8M
EPS estimate-$1.55

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$14.0M
EPS estimate$0.11

Financials

Q4 2024

Income statement

See full
Revenue$43.1M+379%
Operating income-$9.7M+77.0%
Net income-$21.8M+48.4%
EPS (diluted)-$0.66+58.5%

Balance sheet

See full
Cash & equivalents$123.1M+242%
Total debt$16.0M-10.0%
Total equity$70.9M-19.6%
Total assets$483.8M+7.0%

Cash flow

See full
Operating cash flow-$66.7M-94.1%
CapEx$263.0K-6.1%
Free cash flow-$66.9M-93.3%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$402.88M-29.2%
Enterprise value$295.83M-46.3%
P/S4.4×-28.8×

Profitability

See full
Operating margin-125.9%-58.5pp
Net margin-159.1%-72.3pp
FCF margin-148.7%-65.6pp

Returns & leverage

See full
Return on equity-182.7%+3,912pp
Debt / equity0.2×0.0×
Current ratio9.5×-1.4×

FAQ

When did AnaptysBio, Inc. report Q4 2024 earnings?
AnaptysBio, Inc. (ANAB) reported Q4 2024 earnings on February 27, 2025 after market close.
What were AnaptysBio, Inc.'s Q4 2024 revenue and EPS?
AnaptysBio, Inc. reported revenue of $43.1M and eps of $-0.72 for Q4 2024.
Did AnaptysBio, Inc. beat estimates in Q4 2024?
Revenue beat the consensus estimate of $7.8M by $35.3M. EPS beat the consensus estimate of $-1.55 by $0.83.
Where can I find AnaptysBio, Inc.'s Q4 2024 SEC filings?
You can read the 8-K earnings release (0001370053-25-000023) and the 10-K periodic report (0001370053-25-000024) directly on SEC EDGAR. The filing index links above go to sec.gov.